Ribavirin shows immunomodulatory effects on activated microglia

References

• Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007;8:57–69
   PubMed Web of Science ®Google Scholar
• Smith JA, Das A, Ray SK, Banik NL. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 2012;87:10–20
   PubMed Web of Science ®Google Scholar
• Rawji KS, Yong VW. The benefits and detriments of macrophages/microglia in models of multiple sclerosis. Clin Dev Immunol 2013;2013:948976
   Google Scholar
• Kobayashi K, Imagama S, Ohgomori T, et al. Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis 2013;4:e525
   PubMed Web of Science ®Google Scholar
• Peavy DL, Koff WC, Hyman DS, Knight V. Inhibition of lymphocyte proliferative responses by ribavirin. Infect Immun 1980;29:583–589
   Google Scholar
• Jolley WB, Sharma B, Chami R, et al. Long-term skin allograft survival by combined therapy with suboptimal dose of cyclosporine and ribavirin. Transplant Proc 1988;20:703–706
   Google Scholar
• Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998;160:3487–3493
   PubMed Web of Science ®Google Scholar
• Milicevic I, Pekovic S, Subasic S, et al. Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats. J Neurosci Res 2003;72:268–278
   Google Scholar
• Lavrnja I, Stojkov D, Bjelobaba I, et al. Ribavirin ameliorates experimental autoimmune encephalomyelitis in rats and modulates cytokine production. Int Immunopharmacol 2008;8:1282–1290
   PubMed Web of Science ®Google Scholar
• Stojkov D, Lavrnja I, Pekovic S, et al. Therapeutic effects of combined treatment with ribavirin and tiazofurin on experimental autoimmune encephalomyelitis development: clinical and histopathological evaluation. J Neurol Sci 2008;267:76–85
   Google Scholar
• Lavrnja I, Savic D, Bjelobaba I, et al. The effect of ribavirin on reactive astrogliosis in experimental autoimmune encephalomyelitis. J Pharmacol Sci 2012;119:221–232
   Google Scholar
• Jeulin H, Venard V, Carapito D, et al. Effective ribavirin concentration in mice brain using cyclodextrin as a drug carrier: evaluation in a measles encephalitis model. Antiviral Res 2009;81:261–266
   PubMed Web of Science ®Google Scholar
• Jin R, Fossler MJ, McHutchison JG, et al. Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. AAPS J 2012;14:571–580
   Google Scholar
• Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel. AIDS 2007;21:1073–1089
   PubMed Web of Science ®Google Scholar
• Minagar A, Shapshak P, Fujimura R, et al. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 2002;202:13–23
   PubMed Web of Science ®Google Scholar
• Wilkinson J, Radkowski M, Laskus T. Hepatitis C virus neuroinvasion: identification of infected cells. J Virol 2009;83:1312–1319
   PubMed Web of Science ®Google Scholar
• Vivithanaporn P, Maingat F, Lin L-T, et al. Hepatitis C virus core protein induces neuroimmune activation and potentiates human immunodeficiency virus-1 neurotoxicity. PLoS One 2010;5:e12856
   Web of Science ®Google Scholar
• Giulian D, Baker J. Characterization of ameboid mammalian brain microglia isolated from developing mammalian brain. J Neurosci 1986;6:2163–2178
   PubMed Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107–1112
   PubMed Web of Science ®Google Scholar
• Tsubota A, Akuta N, Suzuki F, et al. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Intervirology 2002;45:33–42
   Google Scholar
• Lund S, Christensen KV, Hedtjärn M, et al. The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions. J Neuroimmunol 2006;180:71–87
   PubMed Web of Science ®Google Scholar
• Nakamura Y. Regulating factors for microglial activation. Biol Pharm Bull 2002;25:945–953
   PubMed Web of Science ®Google Scholar
• Vallée S, Fouchier F, Braguer D, et al. Ribavirin-induced resistance to heat shock, inhibition of the Ras-Raf-1 pathway and arrest in G(1). Eur J Pharmacol 2000;404:49–62
   PubMed Web of Science ®Google Scholar
• Piao WH, Wong R, Bai XF, et al. Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis. J Immunol 2007;179:7415–7423
   PubMed Web of Science ®Google Scholar
• Li JM, Yang Y, Zhu P, et al. Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells. Immunopharmacol Immunotoxicol 2012;34:36–41
   PubMed Web of Science ®Google Scholar
• Solbrig MV, Schlaberg R, Briese T, et al. Neuroprotection and reduced proliferation of microglia in ribavirin-treated bornavirus-infected rats. Antimicrob Agents Chemother 2002;46:2287–2291
   Google Scholar
• Boje KM, Arora PK. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res 1992;587:250–256
   PubMed Web of Science ®Google Scholar
• Merrill JE, Ignarro LJ, Sherman MP, et al. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immuno 1993;151:2132–2141
   PubMed Web of Science ®Google Scholar
• Possel H, Noack H, Putzke J, et al. Selective upregulation of inducible nitric oxide synthase (iNOS) by lipopolysaccharide (LPS) and cytokines in microglia: in vitro and in vivo studies. Glia 2000;32:51–59
   PubMed Web of Science ®Google Scholar
• Kryger MBL, Wohl BM, Smith AAA, Zelikin AN. Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug. Chem Commun (Camb) 2013;49:2643–2645
   Google Scholar
• Abd-El-Basset EM, Prashanth J, Ananth Lakshmi KV. Up-regulation of cytoskeletal proteins in activated microglia. Med Princ Pract 2004;13:325–333
   Google Scholar
• Honda S, Sasaki Y, Ohsawa K, et al. Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors. J Neurosci 2001;21:1975–1982
   PubMed Web of Science ®Google Scholar
• Gomes C, Ferreira R, George J, et al. Activation of microglial cells triggers a release of brain-derived neurotrophic factor (BDNF) inducing their proliferation in an adenosine A2A receptor-dependent manner: A2A receptor blockade prevents BDNF release and proliferation of microglia. J Neuroinflammation 2013;10:16
   PubMed Web of Science ®Google Scholar
• Fujita R, Ma Y, Ueda H. Lysophosphatidic acid-induced membrane ruffling and brain-derived neurotrophic factor gene expression are mediated by ATP release in primary microglia. J Neurochem 2008;107:152–160
   Google Scholar
• Abd-el-Basset E, Fedoroff S. Effect of bacterial wall lipopolysaccharide (LPS) on morphology, motility and cytoskeletal organization of microglia in cultures. J Neurosci Res 1995;41:222–237
   Google Scholar
• Ferreira R, Santos T, Viegas M, et al. Neuropeptide Y inhibits interleukin-1β-induced phagocytosis by microglial cells. J Neuroinflammation 2011;8:169
   PubMed Web of Science ®Google Scholar
• Drechsel DN, Kirschner MW. The minimum GTP cap required to stabilize microtubules. Curr Biol 1994;4:1053–1061
   PubMed Web of Science ®Google Scholar
• Hanisch U-K. Microglia as a source and target of cytokines. Glia 2002;40:140–155
   PubMed Web of Science ®Google Scholar
• Rossi S, Furlan R, De Chiara V, et al. Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis. Ann Neurol 2012;71:76–83
   PubMed Web of Science ®Google Scholar
• Rossi S, Studer V, Motta C, et al. Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis. J Neuroinflammation 2014;11:32
   Google Scholar
• Meier V, Bürger E, Mihm S, et al. Ribavirin inhibits DNA, RNA and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection. J Med Virol 2003;69:50–58
   Google Scholar
• De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997–1004
   PubMed Web of Science ®Google Scholar
• Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237–S244
   PubMed Web of Science ®Google Scholar